Business Description
IN8bio Inc
NAICS : 325412
SIC : 2834
ISIN : US45674E1091
Share Class Description:
FRA:6JH: Ordinary SharesDescription
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.73 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.64 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.8 | |||||
| 3-Year EPS without NRI Growth Rate | -23.4 | |||||
| 3-Year FCF Growth Rate | -29.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 31.93 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.19 | |||||
| 9-Day RSI | 38.05 | |||||
| 14-Day RSI | 41.45 | |||||
| 6-1 Month Momentum % | -64.73 | |||||
| 12-1 Month Momentum % | -76.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 1.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.6 | |||||
| Shareholder Yield % | -75.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -193.35 | |||||
| ROA % | -128.6 | |||||
| ROIC % | -259.19 | |||||
| ROC (Joel Greenblatt) % | -337.24 | |||||
| ROCE % | -154.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.38 | |||||
| Price-to-Tangible-Book | 1.49 | |||||
| EV-to-EBIT | -0.71 | |||||
| EV-to-EBITDA | -0.77 | |||||
| EV-to-FCF | -0.79 | |||||
| Earnings Yield (Greenblatt) % | -139.99 | |||||
| FCF Yield % | -121.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IN8bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.689 | ||
| Beta | -0.2 | ||
| Volatility % | 108.04 | ||
| 14-Day RSI | 41.45 | ||
| 14-Day ATR (€) | 0.016496 | ||
| 20-Day SMA (€) | 0.2754 | ||
| 12-1 Month Momentum % | -76.54 | ||
| 52-Week Range (€) | 0.202 - 1.52 | ||
| Shares Outstanding (Mil) | 72.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IN8bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IN8bio Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
IN8bio Inc Frequently Asked Questions
What is IN8bio Inc(FRA:6JH)'s stock price today?
The current price of FRA:6JH is €0.24. The 52 week high of FRA:6JH is €1.52 and 52 week low is €0.20.
When is next earnings date of IN8bio Inc(FRA:6JH)?
The next earnings date of IN8bio Inc(FRA:6JH) is 2025-03-14 Est..
Does IN8bio Inc(FRA:6JH) pay dividends? If so, how much?
IN8bio Inc(FRA:6JH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers